

#5

Sheet 1 of 1

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
13425-055001Application No.
09/988,966**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

Applicant
Björn M. Nilsson, et al.Filing Date
November 19, 2001Group Art Unit
1624**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
FB	AA	4,081,542	Mar. 28, 1978	Lumma, Jr., et al	424	250	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
FB	AJ	WO 00/76984	21.12.00	WIPO	C07D	241/18		
FB	AK	WO 96/11930	25.04.96	WIPO	C07D	471/04		
FB	AL	46-23759 10-095385	12.10.99	Japan (Abstract Only)	C07D	241/04		
	AM							
	AN							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
FB	AO	Lee et al. <i>Effect of the Serotonin Agonist, MK-212, on Body Temperature in Schizophrenia.</i> Biological Psychiatry, 1992:31, pp. 460-470.
FB	AP	Lumma, Jr. et al. <i>Piperazinympyrazines with Central Serotoninmimetic Activity.</i> Journal of Medicinal Chemistry, 1978, Vol. 21, No. 6. pp. 536-542
FB	AQ	Jemrick-Luecke et al. <i>Involvement of 5-HT_{2A} receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.</i> European Journal of Pharmacology, Vol. 311, 1996. pp. 217-211.
FB	AR	Conn et al. <i>Relative Efficacies of Piperazines at the Phosphoinositide Hydrolysis-Linked Serotonergic (5-HT-2 and 5-HT-1c) Receptors.</i> The Journal of Pharmacology and Experimental Therapeutics, Vol. 242, No. 2, 1987. pp. 552-557.

Examiner Signature

L Bernhardt

Date Considered

1/2/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)